https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29865 Wed 24 Jun 2020 12:59:16 AEST ]]> Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45703 Wed 24 Jan 2024 14:33:03 AEDT ]]> Incidence and prevalence of NMOSD in Australia and New Zealand https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34644 Wed 22 May 2019 14:48:36 AEST ]]> Radiofrequency neurotomy for the treatment of third occipital headache https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1714 Wed 11 Apr 2018 09:14:47 AEST ]]> Candidate-gene analysis of white matter hyperintensities on neuroimaging https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25946 Wed 10 Nov 2021 15:20:41 AEDT ]]> The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-Associated disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55423 Tue 28 May 2024 14:56:42 AEST ]]> Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53990 Thu 25 Jan 2024 13:04:15 AEDT ]]> Management of functional communication, swallowing, cough and related disorders: Consensus recommendations for speech and language therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48859 Thu 13 Apr 2023 09:53:17 AEST ]]> Comparison of Bobath based and movement science based treatment for stroke: a randomised controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:9508 Sat 24 Mar 2018 08:35:31 AEDT ]]> Familial recurrence risks for multiple sclerosis in Australia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13657 s) was similar across all sites. The familial recurrence risk of MS in Australia is lower than in previously reported studies. This is directly related to the lower population prevalence of MS. The overall genetic susceptibility in Australia as measured by the λs is similar to the northern hemisphere, suggesting that the difference in population risk is explained largely by environmental factors rather than by genetic admixture.]]> Sat 24 Mar 2018 08:25:18 AEDT ]]> The Audio Recorded Cognitive Screen (ARCS): a flexible hybrid cognitive test instrument https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11471 Sat 24 Mar 2018 08:11:39 AEDT ]]> CT perfusion improves diagnostic accuracy and confidence in acute ischaemic stroke https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19328 Sat 24 Mar 2018 07:52:14 AEDT ]]> The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28472 2 than ≤2. Two-point progression was uncommon for EDSS score of <2 and more common at EDSS score of 4. Conclusions: EDSS rank stability increases with disease duration, probably due to reduced relapses and less random variation in later disease. After 4 years duration, EDSS rank was highly predictive of EDSS rank 5 years later. Risk of progression by 10 years was highly dependent on EDSS score at 5 years duration. We confirm the utility of EDSS ranking to predict 5-year outcome in individuals 4 years after disease onset.]]> Sat 24 Mar 2018 07:39:35 AEDT ]]> Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30101 Sat 24 Mar 2018 07:37:59 AEDT ]]> Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29942 -23). A reciprocal relationship was seen for ambient ultraviolet radiation (UVR), with a significantly increasing AAO for patients with MS per each quartile increment of ambient UVR (p=1.56×10-17). We found that the AAO of female patients was ~5 months earlier than male patients (p=0.002). AAO of progressive-onset patients with MS were ~9 years later than relapsing-onset patients (p=1.40×10-265). Conclusions: An earlier AAO in higher latitude regions was found in this worldwide European-descent cohort and correlated inversely with variation in latitudinal UVR. These results suggest that environmental factors which act at the population level may significantly influence disease severity characteristics in genetically susceptible populations.]]> Sat 24 Mar 2018 07:31:01 AEDT ]]> What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke?: recent insights into mechanisms and potential biomarkers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26464 Sat 24 Mar 2018 07:27:17 AEDT ]]> Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33303 Sat 06 Jul 2024 15:13:18 AEST ]]> Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48108 Mon 27 Feb 2023 15:18:00 AEDT ]]> Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53317 Fri 19 Jan 2024 14:25:45 AEDT ]]> Disability accrual in primary and secondary progressive multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]>